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A B S T R A C T
Objective: To evaluate the efﬁcacy and safety of adjunctive zonisamide (ZNS) therapy in Korean adults
with uncontrolled partial epilepsy.
Methods: Study patients had an average of at least one seizure per 4-week (averaged over a 12-week
historical baseline) despite the use of one to three antiepileptic drugs. The starting dose of ZNS was
100 mg/day, and was increased to 200 mg/day after 2 weeks. During the 12-week maintenance period,
the dose of ZNS was adjusted to 200–400 mg/day based on the physicians’ discretion. The global
evaluation scale (GES) and quality of life (QOLIE-31) were also evaluated.
Results: A total of 121 patients were enrolled, of which 88 patients completed the study. The median
percent reduction in weekly seizure frequency over the treatment period was 59.0%. The 50% and 75%
responder rates were 57.3% and 38.5%, respectively. Seizure freedom over the treatment period was
observed in 25 patients, but seizure freedom throughout the 16-week treatment period was attained in
only 16 patients. On investigator’s GES, 84 patients were considered improved, with 33 patients showing
marked improvement. In QOLIE-31 scale, seizure worry improved signiﬁcantly but emotional well-being
deteriorated. Treatment-emergent adverse events (AEs) were reported in 80 patients. The most common
AEs were dizziness (28.1%), somnolence (24.0%), anorexia (18.2%), headache (14.0%), nausea (13.2%), and
weight loss (10.7%). Twenty-two patients discontinued the trial due to drug-related AEs.
Conclusions: Our results suggest that adjunctive ZNS therapy for the treatment of refractory partial
epilepsy, though efﬁcacious, is associated with signiﬁcant tolerability problems.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Zonisamide (ZNS) has been approved for broad-spectrum use in
Japan since 1989 and in Korea since 1991, while it was licensed as* Corresponding author at: Department of Neurology, Yonsei University College
of Medicine, Severance Hospital, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752,
Republic of Korea. Tel.: +82 2 2228 1603; fax: +82 2 393 0705.
E-mail address: bilee@yuhs.ac (B.I. Lee).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.12.005an adjunctive drug for the treatment of partial seizures much later
in the USA (2000) and Europe (2005).
ZNS’s main pharmacological effects are due to the blockade of
neuronal voltage-gated sodium channels and low-voltage-activat-
ed (T-type) calcium channels.1 ZNS has a favorable pharmacoki-
netic proﬁle. It is rapidly absorbed from the gastrointestinal tract,
and peak plasma concentrations are achieved within 2–5 h after
oral dosing. Oral bioavailability is close to 100%, and the kinetics
are linear after the administration of a single dose of 200–800 mg.2
Steady-state plasma concentrations are achieved within 14 days ofvier Ltd. All rights reserved.
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peak-trough ﬂuctuation of only 14% on twice-daily dosing.3
Although inactivation of ZNS occurs predominantly by hepatic
metabolism involving CYP3A4-mediated reduction, this drug
neither induces nor inhibits hepatic cytochrome P450 isoenzymes
that are implicated in the metabolism of several antiepileptic
drugs (AEDs).4 However, enzyme-inducing AEDs increase its
clearance, an interaction that may necessitate a dosage increase,
but which will also permit more rapid attainment of steady-state
ZNS concentrations. Otherwise, ZNS is essentially devoid of
clinically signiﬁcant interactions with other AEDs, oral contra-
ceptives and, indeed, all other classes of therapeutic agents
investigated to date.5
The efﬁcacy and safety of ZNS in partial epilepsy have been
demonstrated in several pre-registration, randomized, double-
blind, placebo-controlled studies in which this drug was adminis-
tered as adjunctive therapy in drug-resistant epileptic patients
with partial epilepsy.6–9 Long-term open studies as well as double-
blind, placebo-controlled studies have demonstrated that ZNS has
a good efﬁcacy and tolerability proﬁle, supporting its use as an
adjunctive therapy for adult epileptic patients.10–15 A long-term
open-label study13 in 317 patients with refractory partial epilepsy
who completed a ﬁxed-dose, randomized, double-blind, add-on
trial4 showed that patient retention rates at 1, 2, and 3 years were
65.3%, 44.5% and 28.8%, respectively, comparable to those reported
for other AEDs. In indirect comparisons of new AEDs based on
meta-analysis of placebo-controlled add-on trials, ZNS had a
middle ranking in terms of both response and withdrawal
rates.16,17
In this study, we report the results of a pragmatic trial aimed
at assessing the efﬁcacy and safety of ZNS as an add-on therapy
in patients suffering from partial seizures not adequately
controlled despite treatment with up to three other AEDs. We
also report the impact of ZNS on health-related quality of life.
We used an open-label methodology, very similar to routine
clinical practice, with regard to inclusion criteria and dose
escalation.Fig. 1. Study2. Methods
2.1. Study population
Patients 15 years or older with partial seizures, whether or not
secondarily generalized, were eligible for enrolment. Patients had
to have presented with an average of at least one partial seizure per
4 weeks (averaged over a 12-week period preceding study entry)
despite the use of one or three AEDs. Partial seizures were
classiﬁed according to the Commission on the Classiﬁcation and
Terminology of the International League against Epilepsy.18
Patients were not allowed to be taking more than three
concomitant AEDs at the time of study entry, with benzodiazepines
being considered AEDs if taken on a daily basis for any indication.
The AED regimen was required to have been stable for at least
4 weeks prior to study entry. Laboratory values less than two times
the upper normal limits of serum ALT, AST, total bilirubin, BUN, or
creatinine levels were allowed. Patients were excluded if they had
diseases or conditions expected to unduly complicate manage-
ment or evaluation. These included serious psychiatric disorders
within the past 5 years, uncountable seizures or a history of
convulsive status epilepticus within the last year, presence of
known psychogenic nonepileptic seizures within the last year,
progressive degenerative neurological disease, a history of
nephrolithiasis, previous exposure to ZNS, participation in another
clinical study of an investigational drug or device within 12 weeks
of the selection visit, a history of questionable compliance to
scheduled visits or medication intake, pregnant or lactating
females, females of childbearing potential unwilling to utilize a
medically acceptable birth control method, and visual ﬁeld defects
relevant to vigabatrin as a previous or concomitant AED.
2.2. Study design
This therapeutic conﬁrmatory Phase IV open-label, single-arm
study of patients with partial seizures began with a 12-week
historical baseline period followed by a 16-week treatment period design.
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protocol was approved by the Institutional Review Board of each
participating center. It was conducted according to the Interna-
tional Conference on Harmonisation guidelines and the Declara-
tion of Helsinki.
The study was divided into an up-titration period (ﬁrst 4 weeks)
and a maintenance period (last 12 weeks) as shown in Fig. 1. At
visit 1 (week 0), investigators obtained patients’ written informed
consent, collected demographic data and medical/surgical histo-
ries, and performed physical and neurological examinations,
including vital signs and body mass. During the 4-week up-
titration period, patients initially received ZNS 100 mg/day (V1)
(administered qd). The dose was increased to 200 mg/day
(administered bid) after 2 weeks and could be increased to
300 mg/day (administered bid) after an additional 2 weeks (V2)
at the discretion of the investigator if it was clinically necessary to
achieve maximum beneﬁt. During the 12-week maintenance
period, the ZNS dose was allowed to be increased from 200 mg/day
to 300 mg/day or from 300 mg/day to 400 mg/day at V3 (week 8) if
seizure control was insufﬁcient, and decreased on a single occasion
in patients who were receiving 300 mg/day if poorly tolerated. At
week 16, patients made a ﬁfth and ﬁnal visit on completion of the
study, at which time ﬁnal data were collected. Those who elected
not to continue ZNS therapy had their dose reduced gradually.
Patients recorded the date, number, and type of seizures on a daily
record card; each investigator coded the seizures experienced by
his or her patients. Adverse events (AEs) were recorded at each
visit based on spontaneous patient reports, investigator observa-
tions, responses to standard questions asked by the investigator,
and events recorded on the patient daily record card.
2.3. Prior and concomitant therapy
The history of previous AEDs was investigated. For the purposes
of study evaluation, the patients’ concomitant AEDs had to remain
constant during the study. Additional medication was allowed to
be prescribed for the well-being of the patient; however,
medication (other than AEDs) affecting the central nervous system
was to be avoided unless the patient had been on a stable dose for
at least the last 6 months before the ﬁrst visit. Concomitant
medication was maintained at the same stable dose throughout
the study.
2.4. Efﬁcacy and safety measurements
Efﬁcacy end points were based on the frequency of seizures
during the 16-week treatment period (titration and maintenance)
compared with the 12-week baseline period as well as retention
rate. The primary efﬁcacy variables were the percent reduction
from baseline in seizure frequency per week and the retention rate
at week 16, deﬁned as the number of subjects still treated with ZNS
at the end of the 16-week treatment period divided by the number
of patients in the intent-to-treat (ITT) population. Other efﬁcacy
variables included the median reduction in the frequency of
seizures and seizure days per week, the responder rates, and the
number of seizure-free patients. For patients who did not complete
the 16-week treatment period, data up to withdrawal were used in
the analysis of efﬁcacy.
Other variables included global evaluation of disease evolution
and quality of life. A validated Korean version of the original
Quality of Life in Epilepsy Questionnaire (QOLIE-31) instru-
ment19,20 was ﬁlled in at the selection visit and at the end of
the 16-week treatment period or upon early withdrawal. Follow-
ing the completion of treatment, the investigator provided a global
evaluation scale rating to assess the overall change in the severity
of the patient’s illness compared to the start of study medication.The rating was based on overall clinical impression (marked
improvement, moderate improvement, slight improvement, no
change, slight worsening, moderate worsening, and marked
worsening). Safety was assessed according to AEs, physical and
neurological examinations, and laboratory evaluations at visit 1
(week 0) and visit 5 (week 16). Physical examinations included
measurement of vital signs.
2.5. Statistical methods
Safety analyses were performed on the ITT population, which
included all patients who took at least one dose of ZNS. However,
four patients who discontinued the study at the early stage
without any post-treatment seizure count were not included in
the efﬁcacy analyses based on seizure count during the treatment
period. Study variables were summarized by descriptive statis-
tics: mean, median, standard deviation, Q1 and Q3, range for
continuous variables, and frequency tables for categorical
variables. Baseline characteristics (gender, age, etiology of
epilepsy, history of epilepsy, previous and concomitant AEDs)
and ZNS exposure were summarized descriptively for the ITT
population. We used the paired t-test, Wilcoxon’s signed rank test,
Wilcoxon’s rank sum test, or Kruskal–Wallis test to analyze
continuous variables and the x2 test or McNemar’s test to examine
categorical variables.
3. Results
3.1. Demographics
A total of 121 patients were enrolled and formed the ITT
population (Table 1). Of these, 69 (57.0%) were male and 52 (43.0%)
were female. Patients’ ages ranged from 16 to 69 years, with a
mean age (S.D.) of 37.7 (11.2) years. All patients were Korean. The
mean age (S.D.) at onset of epilepsy was 21.2 (12.5) years and the
mean duration (S.D.) of epilepsy was 19.0 (11.8) years. The
etiology of epilepsy was unknown in 55.4% of patients or attributed to
hippocampal sclerosis including a history of signiﬁcant brain insult or
dual pathology (11.6%), cranial trauma (9.9%), atrophic change
without a history of signiﬁcant brain insult (9.1%), cerebral infection
(1.7%), malformation of cortical development (2.5%), cerebral palsy
without a history of signiﬁcant brain insult (2.5%), vascular
malformation (1.7%), stroke (1.7%), tuberous sclerosis (1.7%), perina-
tal injury (0.8%), neuroﬁbromatosis (0.8%), and mental retardation
without a history of signiﬁcant brain insult (0.8%). The median (Q1–
Q3) baseline seizure frequency was 0.50 (0.25–0.92) per week. The
median (Q1–Q3) seizure days were 0.42 (0.25–0.83) per week.
Ninety-three (76.9%) patients presented with at least one complex
partial seizure, 37 (30.6%) patients with at least one secondarily
generalized tonic–clonic seizure, and 13 (10.7%) patients with at least
one simple partial seizure during the baseline 12-week period.
Regarding the history of previous AED treatment, 54 (44.6%) patients
had taken two or more AEDs prior to entry to this study. The majority
(85.1%) of patients entered the trial on two or three concomitant
AEDs. The most frequently used concomitant AEDs were lamotrigine,
valproic acid, topiramate, and levetiracetam.
Of the 121 patients, 88 (72.7%) completed the 16-week
treatment and 33 discontinued the study. Twenty-three patients
withdrew due to an AE, three withdrew because of a lack of
efﬁcacy, and seven withdrew for other reasons (protocol violation
in ﬁve, loss of follow-up in one, and withdrawal of consent in one).
The trial began on February 04, 2008 and ﬁnished on August 30,
2010.
The 121 patients who took one or more doses of ZNS received
the treatment for a mean duration (S.D.) of 94.3 (35.9) days
within the study period. The mean daily dose (S.D.) of ZNS during
Table 1
Baseline demographic and clinical characteristics of the 121 enrolled patients.
Parameter Value
Age, years (mean  S.D.) 37.7  11.2
Gender, male (%) 57.0
Body weight, kg (mean  S.D.)a 65.7  14.0
Height, cm (mean  S.D.)a 164.9  8.7
Body mass index, kg/m2 (mean  S.D.)a 24.0  4.0
Age at onset, years (mean  S.D.) 21.2  12.5
Epilepsy duration, years (mean  S.D.) 19.0  11.8
Weekly partial seizure frequency
Mean  S.D. 1.16  2.3
Median 0.50
Interquartile range (Q1–Q3) 0.25–0.92
Min–max 0.25–21.0
No. of previous antiepileptic drugs (AEDs), n (%)
0 36 (30)
1 31 (26)
2 23 (19)
3 15 (12)
4 13 (11)
5 3 (2)
Previous AEDs taken by 10% of patients, n (%)
Valproic acid 35 (29)
Carbamazepine 25 (21)
Topiramate 23 (19)
Pregabalin 17 (14)
Phenytoin 16 (13)
Clonazepam 13 (11)
Oxcarbazepine 13 (11)
No. of concomitant AEDs, n (%)
1 18 (15)
2 58 (48)
3 45 (37)
Concomitant AEDs taken by 10% of patients, n (%)
Lamotrigine 61 (50)
Valproic acid 50 (41)
Topiramate 43 (36)
Levetiracetam 41 (34)
Carbamazepine 31 (26)
Oxcarbazepine 20 (17)
Pregabalin 13 (11)
a These data were obtained from analysis of 113 patients.
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dose of 261 mg/day. The mean daily dose (S.D.) of exposure over the
last 8 weeks of the individual titration period for subjects completing
the study was 297 (69) mg (range, 200–400 mg).Fig. 2. Median weekly fr3.2. Efﬁcacy
The four patients who discontinued the study (AE in two
patients, withdrawal of consent in one patient, and lack of efﬁcacy
in one patient) without any seizure counts after baseline were not
included in the efﬁcacy analysis. A total of 117 patients were
therefore analyzed. Overall, 90 patients (76.9%) experienced a
reduction from baseline in seizure frequency per week over the
study period; during the last 12 weeks, 84 patients (71.8%)
experienced a reduction from baseline. In the ITT population
(n = 117), the median (Q1–Q3) percent reduction in seizure
frequency was 59.0% (Q1–Q3, 8.3–89.6%) over the treatment
period (range, 3260.0 to 100.0%) (p < 0.001); during the last
12 weeks (n = 102), the median (Q1–Q3) percent reduction in
seizure frequency was 68.5% (Q1–Q3, 18.0–96.3%) over the last 12-
week treatment period (range, 4100.0 to 100.0%) (p < 0.001). The
frequency of seizures decreased from a median (Q1–Q3) of 0.50
(Q1–Q3: 0.33–1.00) per week during the baseline period to a
median of 0.25 (Q1–Q3: 0.06–0.88) per week over the treatment
period. The median seizure frequency was 0.25 per week during
the initial 4 weeks (n = 117, median reduction from base-
line = 53.8%), remained at 0.24 per week during weeks 4–8
(n = 102, median reduction from baseline = 68.4%), then was
0.00 per week during weeks 8–12 (n = 91, median reduction from
baseline = 100.0%), and remained at 0.23 during the last 4 weeks
(n = 89, median reduction from baseline = 84.8%), as shown in
Fig. 2.
Over the treatment period, 57.3% (67/117) of patients had a 50%
or greater reduction in seizures count, 38.5% (45/117) had at least a
75% reduction, and 21.4% (25/117) of patients had a 100%
reduction. During the last 12 weeks, 54.7% (64/117) of patients
had a 50% or greater reduction, 39.3% (46/117) had a 75% or greater
reduction, and 21.4% (25/117) of patients had a 100% reduction.
However, seizure freedom was obtained for a mean of only
6.1 weeks (2.0–12.1 weeks) in nine patients (AEs in six patients,
protocol violation in two patients, and loss of follow-up in one
patient). The mean weekly baseline seizure frequency (S.D.) of 16
patients with seizure freedom completing the study was 0.34 (0.19)
which was signiﬁcantly lower than 1.32 (2.54) of the other patients
(n = 101) (p < 0.001). The mean number of life-time AEDs (previous
and concomitant) of 16 patients with seizure freedom completing the
study was 3.0 (1.8) (range, 1–7) which tended to be lower compared
with 3.9 (1.8) (range, 1–8) of the other patients (n = 101) (p = 0.054).
The mean daily dose of exposure over the last 8 weeks of the
individual titration period for 16 patients with seizure freedom
completing the study was 256 (63) mg (range, 200–400 mg) whichequency of seizure.
Table 3
Treatment-emergent adverse events occurring in 3% or more of enrolled patients
(intent-to-treat population).
Adverse event N (%)
Dizziness 34 (28.1)
Somnolence 29 (24.0)
Anorexia 22 (18.2)
Headache 17 (14.0)
Nausea 16 (13.2)
Weight loss 13 (10.7)
Asthenia 8 (6.6)
Amnesia and impaired judgment 6 (5.0)
Constipation 5 (4.1)
Fatigue 4 (3.3)
K. Heo et al. / Seizure 21 (2012) 188–193192was signiﬁcantly lower than 306 (67) mg (range, 200–400 mg) for
72 patients without seizure freedom completing the study
(p = 0.009).
The median (Q1–Q3) percent reduction in seizure days was
59.3% (Q1–Q3, 5.4–90.1%) over the treatment period (range,
2420.0 to 100.0%) (p < 0.001); during the last 12 weeks, the
median (Q1–Q3) percent reduction in seizure days was 73.0% (Q1–
Q3, 15.7–95.1%) over the treatment period (range, 3050.0 to
100.0%) (p < 0.001). The frequency of seizure days decreased from
a median (Q1–Q3) of 0.42 (Q1–Q3: 0.33–0.83) per week during the
baseline period to a median of 0.24 (Q1–Q3: 0.06–0.79) per week
over the treatment period.
At V3 (week 8), the ZNS dose was increased up to 300 or 400 mg
in 25 patients because of insufﬁcient seizure control; four patients
had a 75% or greater reduction and three patients had a reduction
of 50% or greater but less than 75%, while the remaining 18 patients
had less than 50% reduction over the treatment period.
3.3. Global evaluation scale and QOLIE-31
According to the investigators, 69.4% of patients showed
improvement (marked, 27.3%; moderate, 28.1%; (Q1–Q3, 8.33–
89.6%) slight, 14.0%), while 17.4% of patients showed no change
and 4.1% of patients worsened (moderate in two patients and
marked in three patients). However, the total QOLIE-31 score did
not improve. Seizure worry improved signiﬁcantly (p = 0.013), but
emotional well-being deteriorated (p = 0.007). Health status
showed a tendency to improve (p = 0.086) (Table 2). Of the 97
patients evaluable for quality of life analysis, 49 (50.5%) experi-
enced improvement in their overall QOLIE-31 score.
3.4. Safety
Two hundred and four treatment-emergent AEs were reported
in 80 patients [(66.1%; mean frequency of 2.6 (1.8) per person].
Fifty-one patients (63.8%) had two or more AEs. AEs that emerged in
3% or more of patients during the treatment period are listed in Table
3. The most commonly reported AEs were dizziness (28.1%),
somnolence (24.0%), anorexia (18.2%), headache (14.0%), nausea
(13.2%), and weight loss (10.7%). The majority (99.5%) of treatment-
emergent AEs were mild to moderate in intensity. There were no
signiﬁcant differences in the proportion of patients with AEs (1 AED,
61.1%; 2 AEDs, 67.2%; 3 AEDs, 66.7%) and the mean frequency per
person of AEs [1 AED, 0.9 (0.9); 2 AEDs, 1.8 (2.0); 3 AEDs, 1.8
(2.1)] according to the number of concomitant AEDs. Nine patients
reported AEs leading to a reduction in the ZNS dose. Twenty-three
patients discontinued the trial due to drug-related AEs except for one
patient [mean frequency, 2.7 (1.9) per person; somnolence (n = 8),
dizziness (n = 7), nausea and vomiting (n = 7), headache (n = 5),
anorexia (n = 5), decreased weight (n = 5), asthenia (n = 4), amnesia or
impaired judgment (n = 2), abdominal pain (n = 2), and tremor,
palpitation, pyrexia, abulia, insomnia, rash, paresthesia, etc. in each
one (permitting duplication)]. Five patients discontinued the trialTable 2
Mean QOLIE-31 changes (n = 97).
Domain/item Baseline mean (S.D.) Change mean (S.D.) p value
Seizure worry 47.1 (25.3) 5.5 (21.1) 0.013
Overall QOL 54.1 (15.7) 0.0 (18.6) 0.989
Emotional well-being 58.6 (20.0) 5.9 (20.9) 0.007
Energy/fatigue 47.0 (19.8) 1.4 (17.5) 0.433
Cognitive functioning 65.9 (20.6) 0.2 (19.5) 0.905
Medication effects 53.9 (28.7) 0.6 (26.4) 0.819
Social function 52.8 (25.9) 2.5 (24.0) 0.315
Total score 56.3 (16.2) 0.2 (12.9) 0.888
Health status 53.2 (20.2) 3.7 (21.2) 0.086within the ﬁrst 4 weeks, 12 patients between 4 and 8 weeks, and ﬁve
patients during the last 8 weeks (range, 0.7–13.1). Thirteen patients
(59.1%) had two or more AEs. Two patients experienced serious AEs
(multiple injuries due to a trafﬁc accident and acute diverticulitis,
respectively). These serious AEs were not considered to be related to
ZNS treatment. Psychiatric AEs occurred in six patients (depression in
two patients, abulia in two patients, and agitation, anxiety, and
insomnia, respectively, in three individual patients). None of patients
developed nephrolithiasis.
Neurological examination revealed nervous system abnormali-
ties in 9.1% of patients at baseline; overall, no relevant changes
were observed during treatment. Signiﬁcant decreases in mean
body weight and body mass index were found (65.7–64.0 kg; 24.2–
23.5 kg/m2, p < 0.001). Body weight decreases of at least 5% from
baseline occurred in 22 patients (range 3.5 to 10.0 kg;
representing a weight decrease of 5.7–15.5% from baseline), and
increases of at least 5% occurred in another two patients (range
3.3–6.3 kg; representing a weight increase of 6.3–7.6% from
baseline). There was no signiﬁcant difference between the
proportions of patients who showed signiﬁcant changes (normal
to abnormal or abnormal to normal) in laboratory values of pre-
and post-treatment (data not shown).
4. Discussion
The protocol in the present study followed the usual pattern of
community-based clinical practice in that the dose adjustment of
AED was ﬂexible and patients with less severe epilepsy (median
baseline seizure frequency, 0.5 per week) were recruited.
As expected, the efﬁcacy results of this Korean open-label trial
exceeded the results reported by placebo-controlled, double-
blinded clinical trials6–9 that reported signiﬁcant increases in
reduction in median seizure frequency (up to 41%) and responder
rates (35–42%) following ZNS 400–600 mg/day.21 During the 16-
week treatment, ZNS reduced the weekly frequency of seizures by
a median of 59.0%; 57.3% of patients experienced a reduction in
seizures of 50%, 38.5% had a reduction of 75% or greater, and
21.4% showed seizure freedom, although only 13.7% maintained
seizure freedom for the treatment period. A total of 90 patients
(76.9%) experienced a reduction from baseline in seizure count.
The median percent reduction in seizure days was 59.3%. These
ﬁgures suggest that ZNS is efﬁcacious as an adjunctive drug for the
treatment of partial seizures although considering less refractory
population in this study and overwhelming heterogeneity of non-
comparative studies like this study.22
The most common AEs in this study were dizziness, somno-
lence, anorexia, headache, and nausea, consistent with those
reported in previous placebo-controlled trials. Furthermore, the
number of patients (66.1%) who experienced treatment-emergent
AEs were comparable or slightly lower: 67.9%, 70.9%, and 81.4% for
patients receiving ZNS 100 mg/day, 300 mg/day, or 500 mg/day,
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placebo-controlled trials;21 and 74.4% in a short-term, open-label,
single-arm trial.23 The rate of premature withdrawal (19.0%) was
comparable with that (19.3%) reported from pooled data of placebo-
controlled trials21 and slightly higher than the 15.3% reported for a
multicenter, short-term (19 weeks), open-label, single-arm, add-on
trial.23 Therefore, the proportion of patients who withdrew because
of AEs was relatively high compared with the proportion of patients
with AEs, which suggests that ZNS can cause signiﬁcant AE-related
problems in a speciﬁc population. This result may be related to the
occurrence of multiple AEs in patients. The rates of each AE were
higher than those based on pooled data from placebo-controlled
trials (dizziness, 28.1% vs. 13.3%; somnolence, 24.0% vs. 15.3%;
anorexia, 18.2% vs. 9.6%; headache, 14.0% vs. 6.4%; nausea 13.2% vs.
8.4%).21 Although detailed data are not available regarding the total
number of AEs in placebo-controlled trials, patients with AEs in this
study may have had more AEs per person. The mean number of AEs
among the 80 patients with AEs was 2.6 and the percentage of
patients with more than one AE was 63.8%. Furthermore, the mean
number of AEs in 22 patients with drug-related AEs that led to their
premature withdrawal from the study was 2.7 and the percentage of
patients with more than one AE was 59.1%. The high incidence of
multiple AEs in patients may contribute adversely to the patients’
overall safety despite the mild to moderate degree of severity of each
individual AE. Premature withdrawal occurred more frequently
between 4 and 8 weeks than the ﬁrst 4 weeks (titration period), and
nine patients withdrew prematurely due to AEs despite a seizure-free
state. The high incidence of both multiple AEs and premature
withdrawal may be related to the greater number of concomitant
AEDs (37.2% with three concomitant AEDs) and the more rapid than
optimal titration schedule. However, there were not signiﬁcant
differences in the proportion of patients with AEs and the frequency
per person of AEs according to the number of concomitant AEDs, and
only ﬁve of 22 patients prematurely withdrew ZNS due to drug-
related AEs during the titration period. In fact, the high efﬁcacy but
signiﬁcant tolerability problems associated with ZNS that were found
in this study appear to reﬂect the high rate of improvement in the
investigators’ global evaluation scale and the improvement in seizure
worry without changes or deterioration in the other QOLIE scales.
Our results demonstrate that ZNS is effective in adult Korean
subjects with uncontrolled partial epilepsy when administered at
optimized doses of up to 400 mg/day, as evidenced by the high
efﬁcacy results, although these data were obtained only for short-
term period. However, adjunctive ZNS therapy was associated with
tolerability problems in a signiﬁcant number of patients, as
evidenced by the high rates of premature withdrawal and multiple
AEs per patient.
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